Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

JCI’s Conversations with Giants in Medicine: Katalin Karikó

It has been estimated that in the first six months of 2021, mRNA-based vaccines against SARS-CoV-2 have saved 280,000 lives in the US alone and prevented well over a million hospitalizations. It is the scientific body of work of biochemist Katalin Karikó, Senior Vice President at BioNTech SE, that made these vaccines possible. Karikó’s work into nucleoside modifications to suppress immunogenicity of RNA provided the key to successful vaccines and an exit from the global COVID pandemic. In this episode, Ushma Neill discusses this and much more with Dr. Karikó.

Published November 1, 2021, by Ushma S. Neill

Conversations with Giants in Medicine

Related articles

A conversation with Katalin Karikó
Ushma S. Neill
Ushma S. Neill
Published November 1, 2021
Citation Information: J Clin Invest. 2021;131(21):e155559. https://doi.org/10.1172/JCI155559.
View: Text | PDF
Conversations with Giants in Medicine

A conversation with Katalin Karikó

  • Text
  • PDF
Abstract

Authors

Ushma S. Neill

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts